Abstract

The incidence of thyroid cancer (TC) is increasing annually worldwide, with a growing burden. This study aims to analyze temporal trends in the burden of TC by age and sex in China and globally from 1990 to 2021, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates, and to predict future trends. We obtained data on TC in China and globally from 1990 to 2021 from the Global Burden of Disease (GBD) database. Using the Joinpoint regression model, we calculated and analyzed the trends in age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR). Specifically, we estimated the annual percent change (APC), the average annual percent change (AAPC), and the corresponding 95% confidence intervals (95% CI) for each metric. Additionally, we conducted a decomposition analysis to investigate the impact of aging, population growth, and epidemiological factors on the incidence and mortality rates of TC. Furthermore, the autoregressive integrated moving average (ARIMA) model was employed to predict the burden of TC from 2022 to 2036.  From 1990 to 2021, the ASIR for TC in China increased from 1.249 (95% uncertainty interval [UI]: 1.009–1.473) per 100,000 to 2.473 (95% UI: 1.993–3.088) per 100,000. Conversely, the ASMR decreased from 0.473 (95% UI: 0.403–0.550) per 100,000 to 0.387 (95% UI: 0.307–0.472) per 100,000. Both males and females demonstrated an upward trajectory in ASIR. However, while the ASMR for females decreased, that for males showed an overall increase despite a decline in the last decade. The age of peak onset for TC ranged from 30 to 79 years, whereas the age of peak mortality was between 50 and 89 years. The analysis using the AAPC indicates that the growth in the ASIR (AAPC = 2.242, 95% CI: 2.112–2.371) and ASPR (AAPC = 2.975, 95% CI: 2.833–3.117) in China exceeds the global rate. Furthermore, the reduction in ASMR (AAPC = -0.651, 95% CI: -0.824 - -0.479) and ASDR (AAPC = -0.590, 95% CI: -0.787 - -0.392) in China is also more pronounced than globally. Decomposition analysis indicates that the increasing TC burden in China is primarily driven by population aging, whereas globally, population growth plays a more significant role. Projections based on predictive models suggest that from 2021 to 2036, the ASIR for both China and the global population is expected to continue rising, while the ASMR is anticipated to decline further.  The incidence rates of TC in China and globally have shown a continuous upward trend, which is expected to persist over the next 15 years. Additionally, although the number of male TC cases is relatively lower compared to females, the overall ASMR and ASDR for males have shown an upward trend, despite a slight decline in recent years. This highlights the need to enhance prevention, diagnosis, and treatment measures, and to develop differentiated screening and treatment strategies based on age and sex.

Details

Title
Temporal trends of thyroid cancer in China and globally from 1990 to 2021: an analysis of the global burden of Disease Study 2021
Author
Huang, Kaiyuan 1 ; Huang, Xuanwei 2 ; Qian, Shuoying 2 ; Cai, Yuan 2 ; Wu, Fan 3 ; Luo, Dingcun 4 

 The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, China; Westlake University, Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315) 
 The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, China (GRID:grid.494629.4); Westlake University, Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315) 
 Westlake University, Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315) 
 The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, China (GRID:grid.494629.4); Westlake University, Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315); Zhejiang Normal University, College of Mathematical Medicine, Jinhua, China (GRID:grid.453534.0) (ISNI:0000 0001 2219 2654) 
Pages
25538
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3121050726
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.